Trust the original IL-17 inhibitor with the most in-market experience1-3*†
*First IL-17A antagonist approved by the FDA in 2015.1-3
†Across rheumatology and dermatology.
‡Studied in patients since 2007. FDA approved for moderate to severe PsO in adults in 2015, for active PsA and AS in adults in 2016, for active nr-axSpA with objective signs of inflammation in adults in 2020, for moderate to severe PsO in children 6 years and older, active PsA in children 2 years and older, and active ERA in children 4 years and older in 2021, for moderate to severe HS in adults in 2023, and for moderate to severe HS and active AS in patients 12 years and older in 2026.1,4,8
§Data based on on-label indication by dermatologists’ and rheumatologists’ total prescriptions volume for IL-17 antagonist drugs. Based on projected IQVIA national data.5
||As of December 2025. SC prescriptions across all indications.6
¶Based on number of patients studied in completed clinical trials with IL-17 antagonists, IL-23 antagonists, and IL-12/23 antagonists.7
Definitions
AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; FDA, US Food and Drug Administration; HS, hidradenitis suppurativa; IL, interleukin; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SC, subcutaneous.
References
1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
2. Taltz. Prescribing information. Eli Lilly & Co.
3. Siliq. Prescribing information. Bausch Health US LLC.
4. Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008.
5. Data on file. IL-17 for Rheumatology and Dermatology. Novartis Pharmaceuticals Corp; February 2026.
6. Data on file. Cosentyx Patient Count and TRx. Novartis Pharmaceuticals Corp; February 2026.
7. Data on file. Summary of Approved IL Antagonist Trials. Novartis Pharmaceuticals Corp; February 2026.
8. Cosentyx FDA approval history. Drugs.com. Accessed March 16, 2026. https://drugs.com/history/cosentyx.html